Health

STAT+: Pharmalittle: We’re reading about drug launch prices, an AstraZeneca AI deal, and more

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 20/10/2026, 14:06:24 UTC.

Briefings

STAT+ reports that median net launch prices for 202 newly launched medicines rose 35% to $257,000 in 2025 compared to $190,000 in 2022, with one in four drugs exceeding $500,000. The article also notes Novo Nordisk's CagriSema showed 25% average weight loss in a late-stage study of 2,309 women, though the full trial yielded 22.7% weight loss. Coverage is limited to the provided text, which cites the Institute for Clinical and Economic Review and West Health for the price data.

Key points

• Median net launch prices for 202 newly launched medicines rose 35% to $257,000 in 2025 compared to $190,000 in 2022.
• One in four drugs launched in 2025 had an annual net price exceeding $500,000.

Context

STAT+ analyzes drug launch prices, citing an analysis by the Institute for Clinical and Economic Review and West Health. The article also covers Novo Nordisk's CagriSema weight loss trial results.

Limitations

Evidence is limited to the provided text, which cites external sources for price data and drug trial results. The article does not provide additional background on why these findings matter or what remains unknown about the broader market context.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 20/10/2026, 14:31:04 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeiapciytck43cn7ms2x5acmhuwb6va4ox7dbgy7h4fn4qmgxd62zee